Chinese Japanese Germany Korea
ChemicalBook >> CAS DataBase List >>BMS-986165

BMS-986165

BMS-986165 Structure
BMS-986165 structure
CAS No.
1609392-27-9
Chemical Name:
BMS-986165
Synonyms
Deucravacitinib;6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl) phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide;Tyk2-IN-4;Deucravacitinb;BMS-986165 API;BMS-986165, >98% (HPLC);Deucravacitinib (TYK2-IN-4;Deucravacitinib(BMS986165);Deucravacitinib, 10 mM in DMSO;TYK2-IN-4;BMS986165;BMS-986165;BMS 986165
CBNumber:
CB74808663
Molecular Formula:
C20H22N8O3
Molecular Weight:
422.45
MDL Number:
MOL File:
1609392-27-9.mol
Last updated:2025-04-17 18:22:24
Request For Quotation

BMS-986165 Properties

storage temp. Store at -20°C
solubility DMF: 1 mg/ml; DMSO: 1 mg/ml; DMSO:PBS (pH 7.2) (1:2): 0.33 mg/ml
form A crystalline solid
color Off-white to light yellow
FDA UNII N0A21N6RAU

SAFETY

Risk and Safety Statements

Symbol(GHS)  GHS hazard pictograms
GHS08
Signal word  Danger
Hazard statements  H361f-H372
Precautionary statements  P260-P264-P270-P314-P501

BMS-986165 price

Manufacturer Product number Product description CAS number Packaging Price Updated Buy
ChemScene CS-0065044 BMS-986165 99.79% 1609392-27-9 10mg $350 2021-12-16 Buy
ChemScene CS-0065044 BMS-986165 99.79% 1609392-27-9 50mg $850 2021-12-16 Buy
DC Chemicals DC12174 Deucravacitinib(BMS986165) >98% 1609392-27-9 250mg $1100 2021-12-16 Buy
DC Chemicals DC12174 Deucravacitinib(BMS986165) >98% 1609392-27-9 1g $2200 2021-12-16 Buy
Crysdot CD31005021 6-[(Cyclopropylcarbonyl)amino]-4-{[2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl]amino}-N-(2H3)methyl-3-pyridazinecarboxamide 98% 1609392-27-9 5mg $450 2021-12-16 Buy
Product number Packaging Price Buy
CS-0065044 10mg $350 Buy
CS-0065044 50mg $850 Buy
DC12174 250mg $1100 Buy
DC12174 1g $2200 Buy
CD31005021 5mg $450 Buy

BMS-986165 Chemical Properties,Uses,Production

Uses

BMS-986165 is a novel oral selective TYK2 inhibitor with a unique mechanism of action that is expected to provide a promising oral option to help patients effectively manage their psoriasis.

Uses

Deucravacitinib is a tyrosine kinase 2 inhibitor which can be useful in the treatment of systemic lupus erythematosus.

General Description

Deucravacitinib, a highly selective allosteric TYK2 inhibitor, received its first approval from the FDA in 2022 for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy protein and lipid kinases and pseudokinases with the exception of BMPR2 (IC50 = 193 nM) and JAK1 JH2 pseudokinase domain (IC50 = 1 nM). Despite its potent affinity for JAK1 JH2, deucravacitinib elicited low functional activity in a JAK1/JAK3-dependent IL-2 stimulated cellular assay. BMS-986202 displays >10,000-fold selectivity for TYK2 JH2 over a diverse panel of 273 kinases and pseudokinases that include JAK family members. Like deucravacitinib, its high binding affinity to JAK1 JH2 (IC50 = 7.8 nM) did not translate to functional activity in the cellular assay.

Pharmacokinetics

The crystalline free base form of deucravacitinib exhibited poor aqueous solubility (5.2 μg/mL), which was still acceptable for preclinical studies. It showed moderate half-lives of 4?5 h across species (mouse, dog, and monkey). Excellent exposures and high bioavailability (F > 85%) in mice, dogs, and monkeys were obtained from oral pharmacokinetic studies at a 10 mpk dose. Following oral administration of deucravacitinib, the major metabolite in human plasma was the cyclopropyl carboxamide hydrolytic cleavage product 4 (6-amino-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-methylpyridazine-3-carboxamide).

IC 50

Tyk2 JH2: 0.2 nM (IC50); JAK1 JH2: 1 nM (IC50); IL-12; IL-23

BMS-986165 synthesis

6228-73-5
1609394-23-1
1609392-27-9
Synthesis of BMS-986165 from CYCLOPROPANECARBOXAMIDE and BMS-986165 Related Compound 6

BMS-986165 Preparation Products And Raw materials

Raw materials

2-Methoxy-3-nitrobenzamide BMS-986165 Related Compound 6 2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)aniline 3-(2-methoxy-3-nitrophenyl)-1-methyl-1H-1,2,4-triazole 3-(2-methoxy-3-nitrophenyl)-1H-1,2,4-triazole
METHYL-2-METHOXY-3-NITROBENZOATE METHYL-D3-AMINE HYDROCHLORIDE ethyl 4,6-dihydroxypyridazine-3-carboxylate Ethyl 4,6-dichloropyrridazine-3-carboxylate METHYL 2-HYDROXY-3-NITROBENZOATE
CYCLOPROPANECARBOXAMIDE 3-Nitrosalicylic acid

1of3

Preparation Products

BMS-986165 Suppliers

Global( 210)Suppliers
Supplier Tel Email Country ProdList Advantage
Zhengzhou Anbu Chem Co.,Ltd 		+86-0371-88006763; +8615988602810 sales@anbuchem.com China 2998 58
Hangzhou ICH Biofarm Co., Ltd 		+86-0571-28186870; +undefined8613073685410 sales@ichemie.com China 1015 58
hebei hongtan Biotechnology Co., Ltd 		+852-6619 3215 +86-17731935328 sales03@chemcn.cn China 970 58
BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD. 		+86-18600796368 +86-18600796368 sales@sjar-tech.com China 485 58
Cangzhou Kangrui Pharma Tech Co. Ltd., 		+86-18632776803 +86-13833998158 cangzhoukangrui@126.com China 739 58
Jinan Jianfeng Chemical Co., Ltd 		+86-0531-88110457 +86-15562555968 info@pharmachemm.com China 334 58
BOC Sciences 		+1-631-485-4226 inquiry@bocsci.com United States 19552 58
CONIER CHEM AND PHARMA LIMITED 		+8618523575427 sales@conier.com China 49732 58
Zhengzhou Alfa Chemical Co.,Ltd 		+8618530059196 sale04@alfachem.cn China 12205 58
TargetMol Chemicals Inc. 		+1-781-999-5354 +1-00000000000 marketing@targetmol.com United States 32159 58
Supplier Advantage
Zhengzhou Anbu Chem Co.,Ltd 		58
Hangzhou ICH Biofarm Co., Ltd 		58
hebei hongtan Biotechnology Co., Ltd 		58
BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD. 		58
Cangzhou Kangrui Pharma Tech Co. Ltd., 		58
Jinan Jianfeng Chemical Co., Ltd 		58
BOC Sciences 		58
CONIER CHEM AND PHARMA LIMITED 		58
Zhengzhou Alfa Chemical Co.,Ltd 		58
TargetMol Chemicals Inc. 		58

View Lastest Price from BMS-986165 manufacturers

Image Update time Product Price Min. Order Purity Supply Ability Manufacturer
Deucravacitinib pictures 2025-04-18 Deucravacitinib
1609392-27-9
 US $0.00-0.00 / g 10g 98% 5kgs Cangzhou Kangrui Pharma Tech Co. Ltd.,
BMS-986165 pictures 2025-03-21 BMS-986165
1609392-27-9
 US $0.00 / KG 0.1KG 98% 1000KGS Zhengzhou Anbu Chem Co.,Ltd
BMS-986165 API pictures 2025-03-04 BMS-986165 API
1609392-27-9
 US $100.00-80.00 / KG 1KG 99.9% 500 hebei hongtan Biotechnology Co., Ltd
  • Deucravacitinib pictures
  • Deucravacitinib
    1609392-27-9
  • US $0.00-0.00 / g
  • 98%
  • Cangzhou Kangrui Pharma Tech Co. Ltd.,
  • BMS-986165 pictures
  • BMS-986165
    1609392-27-9
  • US $0.00 / KG
  • 98%
  • Zhengzhou Anbu Chem Co.,Ltd
  • BMS-986165 API pictures
  • BMS-986165 API
    1609392-27-9
  • US $100.00-80.00 / KG
  • 99.9%
  • hebei hongtan Biotechnology Co., Ltd

BMS-986165 Spectrum

BMS-986165(1609392-27-9)1HNMR
Tyk2-IN-4 TYK2-IN-4;BMS986165;BMS-986165;BMS 986165 Deucravacitinib(BMS986165) Deucravacitinib (TYK2-IN-4 6-cyclopropaneamido-4-{[2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl]amino}-N-(2H?)methylpyridazine-3-carboxamide DeucravacitinibQ: What is Deucravacitinib Q: What is the CAS Number of Deucravacitinib 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl) phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide Deucravacitinib Janus kinase,inhibit,JAK,Interleukin Related,Interferon-alpha/beta receptor,BMS 986165,Interferon-α/β receptor,IFNAR,Inhibitor,Deucravacitinib,BMS986165 6-[(Cyclopropylcarbonyl)amino]-4-[[2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl]amino]-N-(methyl-d3)-3-pyridazinecarboxamide 6-(cyclopropanecarbonylamino)-4-[2-methoxy-3-(1-methyl-1,2,4-triazol-3-yl)anilino]-N-(trideuteriomethyl)pyridazine-3-carboxamide Deucravacitinb BMS-986165 API BMS-986165, >98% (HPLC) Deucravacitinib, 10 mM in DMSO 1609392-27-9 API APIS API